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A B S T R A C T
Styrylquinolines are a novel group of quinoline drugs that are known to have p53-independent
antiproliferative activity and antiviral properties. This study evaluated the antifungal activity of these
drugs more deeply, particularly their activity modulation towards Cdr1p, the main multidrug transport-
er of Candida albicans. Styrylquinolines were found to have antifungal activity and to work synergistically
with fluconazole. Additionally, they decreased the extracellular concentration of rhodamine 6G in ABC-
transporter-expressing cells. The cellular localization of GFP-tagged Cdr1p was assessed by epifluorescent
microscopy. Styrylquinolines induce expression of Cdr1p, as confirmed byWestern blotting. Three of four
drugs tested caused the partial delocalization of transport protein to the cytoplasm. These results show
the first evidence that styrylquinolines decrease the activity of ABC multidrug transporters in C. albicans.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Candida albicans is one of the leading causes of opportunistic
mycoses, including hospital-borne infections. Most commonly, it
causes superficial but often persistent oral or vaginal candidiasis.
However, in patients with immunodeficiency infection, life-
threatening systemic candidiasis can occur [1]. C. albicans can gain
different mechanisms of resistance to commonly used antifungals
such as azoles. The main reason for C. albicans drug resistance is
the presence of ABC and MFS transporters in the plasma mem-
brane. Three efflux pumps are responsible for decreasing the
intracellular concentration of azoles. These pumps are encoded by
genes for candida drug resistance (CDR1 and CDR2) and multidrug
resistance (MDR1). These proteins differ in the source of energy used
for their activity and in their specificity to drug molecules [2]. The
use of efflux pump inhibitors [3], or the synergistic action of two
or more drugs with different mechanisms of action [4] could resolve
the problem of candida drug resistance.
Oneof themostpopular structural scaffolds is 8-hydroxyquinoline,
which is found inmany biologically active natural products and ther-
apeuticagents [5]. Itsderivativeshavenumerousapplications, including
antimicrobial agents for both Gram-negative and Gram-positive
bacteria [6], antiviral [7] and anticancer [8] therapy, anti-epileptic and
anti-obesity treatments [9], and painmanagement drugs [10]. It gen-
erally has comparably low cytotoxicity andhigh clinical applicability.
Additionally, it is widely used as fungistatics in agriculture [11]. For
this reason, the quinoline moiety has been considered among other
mono- and diazanaphthalene scaffolds as a privileged structure that
is believed to produce active molecules more often [12].
Styrylquinolines consist of quinoline and phenyl rings con-
nected with an unsaturated ethylene linker, which results in a flat
and rigid conformation that is structurally related to amphoteri-
cin B (AmB) and naftifine. Styrylquinolines are known to inhibit HIV
integrase [13] and have p53-independent antiproliferative activi-
ty [14]. Due to their structure and lipophilic character, they can
interact with the cell membrane during passive transport. As with
other quinoline derivatives, styrylquinolines are known to have
potent antifungal activity. However, their mechanism of action is
largely unexplored. While 8-hydroxyquinoline may act as a metal
chelator and disrupt cell wall biosynthesis, it has been suggested
recently that the mechanism of action may consist of more complex
interactions [15]. Moreover, in more complex quinoline deriva-
tives, it has been shown that metal chelation only plays a minor role
in their antifungal activity [11,16]. Other 8-hydroxyquinoline de-
rivatives are postulated to act as inhibitors of (1,3)-β-d-glucan
synthase, chitin synthase [17] or P450 14-α-demethylase [18], or
by changing the pH in the phagocytic vacuole [19]. This study ex-
amined styrylquinolines as possible inhibitors of C. albicans ABC
transporters. The results demonstrate that these compounds work
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synergistically with fluconazole, and also inhibit the efflux of rho-
damine 6G (R6G), a known substrate for ABC pumps.
2. Materials and methods
2.1. Compounds
All four styrylquinolines were obtained as part of the search for
novel active antifungal agents [16,20]. They were synthesized ac-
cording to knownmethods from aromatic aldehydes and appropriate
quinaldines [14,21]. Stepwise partial hydrolysis was afforded in acety-
lated (WK14B,WK15B) or fully hydrolysed products (WK14,WK15).
After column chromatography purification, the compounds were
used for biological tests. Styrylquinolines, fluconazole (Sigma Aldrich,
Poznan, Poland) and AmB (Sigma Aldrich) were dissolved in di-
methyl sulphoxide (DMSO, Bioshop, Rzeszów, Poland), and
fluphenazine (Sigma Aldrich) was dissolved in sterile water.
2.2. Strains and growth media
The C. albicans strains used in this study were a generous gift
from Prof. Dominique Sanglard (Table 1). All strains were kept as
frozen stocks in glycerol at −80 °C and grown routinely at 28 °C on
YPD medium with 2% dextrose, 1% Bacto peptone (Difco, Warsaw,
Poland) and 1% yeast extract (Difco). For all experiments, with the
exception of a rhodamine 6G assay, strains were subcultured in yeast
nitrogen base (YNB) liquid medium [0.67% YNB (Difco) and 2% dex-
trose] at 28 °C and diluted to desirable optical density at 600 nm
(OD600). For growth on solid media, 2% agar (Difco) was added.
2.3. Susceptibility testing
Drug susceptibility testing was performed in microtitre plates
with two-fold serial dilutions of tested compounds (Fig. 1) according
to the European Committee on Antimicrobial Susceptibility Testing
(EUCAST E.DEF 7.3) specifications with modifications. Cultures were
grown for 18 h in YNB and diluted to A600 of 0.1 in a total volume
of 200 μL, with the tested compound in concentration so that the
DMSO concentration was 1%. Microtitre plates were incubated at
28 °C for 24 h, shaken, and optical densities were read with a
microtitre plate reader at a wavelength of 600 nm. The results are
presented as the percentage of growth relative to control samples,
and MIC50 values are given as the lowest concentration inhibiting
50% of growth according to EUCAST standards. The experiment was
performed in three biological replicates with three technical rep-
licates for each of the four styrylquinolines.
2.4. Fluconazole–styrylquinoline combination assays
Interactions between fluconazole and tested drugs (Fig. 1) were
measured by obtaining the fractional inhibitory concentration (FIC)
index values [26]. Cultures were grown for 18 h in YNB and diluted
to A600 of 0.1 in a total volume of 200 μLwith amixture of fluconazole
and styrylquinoline, each at a starting concentration of MIC50.
Microtitre plates were incubated at 28 °C for 24 h, shaken, and optical
densities were read with a microtitre plate reader at a wavelength
of 600 nm. The sum of the FICs (ΣFIC) was calculated for each well
with the equation ΣFIC = FICA + FICB = (MICA + B/MICA) + (MICB + A/
MICB), where MICA and MICB are the MICs of drugs A and B alone,
respectively, and MICA + B and MICB + A are the concentrations of
the drugs in combination, respectively, in all the wells correspond-
ing to an MIC50. The experiment was performed in three biological
replicates with three technical replicates.
2.5. Permeability assays
Yeast cultures were subcultured overnight in YNB and diluted to
OD600 of 0.4 in fresh medium. The styrylquinoline compounds, flu-
phenazine (Sigma Aldrich) or AmB (Sigma Aldrich) were added and
incubated at 28 °Cwith shaking at 180 rpm. Aliquots of cultures were
taken after 4 h and stained with propidium iodine [27,28] for 5 min
at room temperature to assessmembrane permeability. Observations
were made using fluorescent microscopy (Zeiss AxioVision, Poznan,
Poland). The experiment was performed in three biological replicates.
2.6. Western blotting
The assay was performed in accordance with a previous method
[29] with modifications. Crude protein extract was prepared from
Table 1
Collection of Candida albicans strains used in this study.
Strain Genotype Reference
CAF 2-1 ura3Δ::imm434/URA3 [22]
DSY 448 cdr1Δ::hisG-URA3-hisG/cdr1Δ::hisG [23]
DSY 653 cdr2Δ::hisG-URA3-hisG/cdr2Δ::hisG [24]
DSY 654 cdr1Δ::hisG/cdr1Δ::hisG cdr2Δ::hisG-URA3-hisG/
cdr2Δ::hisG
[24]
ASCa1 ura3Δ::imm434/URA3 CDR1-GFP [25]
Strain CAF 2-1 was treated as the wild-type strain.
Fig. 1. Styrylquinoline compounds used in this study.
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cell suspensions after 4 h of induction with the tested com-
pounds. Aliquots of cell suspensions were pelleted by centrifugation
at 2260 × g for 5 min and resuspended in 1 mL of deionized
water. Cells were lysed by adding 150 μL of 1.85 M NaOH–7.5%
β-mercaptoethanol and incubated on ice for 10 min. Proteins were
precipitated by adding 150 μL of 50% trichloroacetic acid and in-
cubated on ice for 10 min. Samples were centrifuged at 10,000 × g
for 5 min at 4 °C, washed in 1 mL of 1 M Tris–HCl pH 8.0, and re-
suspended in 50 μL of sample buffer (40 mM Tris–HCl, 8 M urea, 5%
SDS, 0.1 mM EDTA 1% β-mercaptoethanol, 0.1 mg/mL bromophe-
nol blue). Following incubation at 37 °C for 30 min, samples were
loaded on 6% sodium dodecyl sulphate–polyacrylamide gel and de-
veloped in a Mini-PROTEAN II electrophoresis cell (Bio-Rad, Poznan,
Poland). Samples were then transferred onto nitrocellulose mem-
brane using a Mini-PROTEAN Tetra System electrophoresis cell (Bio-
Rad). Membranes were stained with Poncau S to check for equal
loading of gels. Immunodetection of Cdr1p was performed using
polyclonal mouse anti-GFP antiserum and horseradish-peroxidase-
conjugated antimouse antiserum as a secondary antibody. Signals
were detected using an ECL kit (PerkinElmer, Krakow, Poland) ac-
cording to the manufacturer’s instructions. The experiment was
performed in four biological replicates.
2.7. Rhodamine 6G assay
R6G assay was performed according to Nakamura et al [30]
with modifications. The cell culture was pelleted in the log phase
and washed twice in double-distilled water and once in HEPES
buffer (50 mM, pH 7.0). Cells were diluted in fresh HEPES buffer to
OD600 of 1.0 and incubated for 60 min at 30 °C and 200 rpm with
5 mM 2-deoxy-d-glucose (Sigma Aldrich). Next, the tested com-
pounds were added in half MIC50 concentrations, and cells were
incubated for 5 min in the same conditions. Next, 10 μM R6G was
added and the cell suspension was incubated for an additional
90 min. Cells were pelleted, washed twice in HEPES buffer, and
suspended in fresh HEPES at OD600 of 10.0. The cell suspension
was incubated for 5 min at 30 °C with shaking, R6G efflux was
initiated by adding 10 mM glucose, and suspensions were incu-
bated for 30min with aliquots removed at 15-min intervals. Aliquots
of 400 μL were pelleted, and three duplicates of 100 μL of super-
natant were added to black microtitre plates. Fluorescence was
measured in a Cary Eclipse spectrofluorimeter (Agilent Technolo-
gies, Santa Clara, CA, USA) at an excitation wavelength of 529 nm
(slit 5) and emission of 553 nm (slit 10). The experiment was
performed in three biological replicates with three technical
replicates.
2.8. Cytotoxicity assay
Normal human fibroblasts were grown in MEM alpha medium
with foetal bovine serum supplementation at 5%. Cells were cul-
tured in 25-cm2 tissue culture flasks at 37 °C in 5% CO2/95%
humidified air, and passaged twice per week, using 0.25% trypsin
solution with 0.05% EDTA added. Cells were seeded in 96-well plates.
Theywere grown for 24 h and styrylquinoline cytotoxicity was tested
by MTT assay [31]. Styrylquinolines were added to the cells and in-
cubated for 48 h, after which 5 μL of MTT stock solution (5 mg/mL)
was added. Cells were incubated for 4 h at 37 °C. Following removal
of the medium, 50 μL of DMSO was added to the cells and plates
were stirred for 10 min. The absorbance of formazan, a metabolite
of MTT, was measured at a wavelength of 570 nm using an ASYS
UVM340 microplate reader (Biogenet, Jozefow, Poland). The exper-
imentwas performed in two biological replicates with three technical
replicates.
3. Results
3.1. Antifungal activity of styrylquinolines
The MICs of styrylquinolines were determined for the wild-type
strain and for single and double cdrΔ mutants. All four tested drugs
were diluted in DMSO and then diluted in YNB to final concentra-
tions of 0.4, 0.2, 0.1 and 0.05mM, followed by incubation for 24 h
as described above. The two compounds with a hydroxyl group in
the phenyl ring,WK14 andWK15, had the lowestMIC50 values among
the drugs tested (Table 2). Control compounds 8-hydroxyquinoline
and 8-hydroxyquinaldine had a similar effect on the strains.
Substitution of an acetoxy group in the same positions (WK14B,
WK15B) decreased drug activity, particularly for cdr2Δ and wild-
type strains. In general, the cells with CDR1 deletion showed a
significant increase in sensitivity to styrylquinolines in contrast to
8-hydroxyquinoline and 8-hydroxyquinaldine, suggesting that
styrylquinolines are Cdr1p substrates. This indicates a possible mode
of action as competitive inhibitors of this transporter. As Cdr1p has
a higher impact on fluconazole resistance than Cdr2p, the strain
without Cdr1p transporters is characterized by a lower fluconazole
MIC than strains that express Cdr1p transporters (0.25 μg/mL vs.
2 μg/mL for cdr2Δ and wild-type strains). However, the simultane-
ous presence of fluconazole and styrylquinolines abolishes the Cdr1p-
induced resistance, as evidenced by the FIC index values in Table 3.
No synergistic effect was observed in the case of the cdr1Δ strain.
This presumably occurs because styrylquinolines only have a minor
effect on Cdr2p, as the MIC profile of the cdr1Δ strain is comparable
with that of the wild-type strain (Table 2). Interestingly, the com-
pound with the highest synergistic activity, WK14B, has acetoxy
groups in both the phenyl and quinolone rings. For all subsequent
studies, the styrylquinoline concentration was half MIC50 if not noted
otherwise.
3.2. Styrylquinolines inhibit R6G efflux
One of the hypotheses explaining the preference for some struc-
tures in synergistic activity is the competitive export of compounds
with varying intensity outside the cells. An R6G efflux assay was
used to determine if styrylquinolines can influence ABC transport-
ers in C. albicans. Tested compounds are structurally related to AmB,
which may result in membrane permeabilization, so this drug was
used as a control. As expected, high levels of R6G were absorbed
Table 2
Minimum inhibitory concentration (mM) at which 50% of isolates were inhibited
(MIC50) for tested styrylquinoline compounds (n = 3).
Wild-type cdr1Δ cdr2Δ cdr1Δ cdr2Δ
WK14B >0.4 0.1 >0.4 0.05
WK15B >0.4 0.4 >0.4 0.1
WK15 0.1 0.01 0.2 0.01
WK14 0.1 0.1 0.1 0.05
8HQ 0.12 0.25 0.12 0.12
8HQD 0.12 0.25 0.12 0.12
AmB 0.001 0.001 0.001 0.001
Table 3
Synergistic effect of tested compounds and fluconazole on Candida albicans strains.
The results are presented as fractional inhibitory concentration values for tested
styrylquinoline compounds (n = 3).
Wild-type cdr1Δ cdr2Δ
WK14B 0.26 1 0.03
WK15B 0.26 1.2 0.02
WK15 2 1 2
WK14 1 2 1
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in the sample treated with AmB (Fig. 2). However, as in the
fluconazole synergy experiment, WK14B and (surprisingly) WK14
showed inhibition of R6G efflux. WK15 and WK15B had no effect
on R6G export from cells. It seems that the change of substituents
in the ortho position on the phenol ring reduced the affinity of these
compounds for pumps and efflux from the cell. However, in com-
bination with fluconazole, WK15B was more active than WK15,
indicating that the –OAc group is significant for synergistic action
of the tested drugs.
To confirm that the cell membrane of C. albicans is not dis-
rupted, cells treated with styrylquinolines were stained with non-
permeable dye propidium iodine and observed under a fluorescent
microscope. As shown in Fig. 3a, none of the tested compounds
showed red staining characteristic of membrane disruption, as shown
in cells after treatment with AmB. However, when the concentra-
tion of styrylquinolines was increased, cells were stained with
propidium iodine (Fig. 3b).
3.3. Styrylquinolines induce Cdr1p production and affect its
localization in cells
The treatment of C. albicans cells with ABC transporter sub-
strates increases their expression [32]. Fluorescentmicroscopy (Fig. 3)
shows a stronger signal from GFP-tagged Cdr1p for cells incu-
bated with styrylquinolines than control samples. The Cdr1p-GFP
protein level in crude extract was also higher in treated cells (Fig. 4).
WK14B, WK14 and WK15 at half MIC50 showed partial delocaliza-
tion of the signal to the inside of the cell (Fig. 3). At concentrations
higher than MIC50 of WK14 and WK15, the signal came from the
whole cells (Fig. 3b). The AmB-positive control for delocalization
showed complete intracellular delocalization of the signal, but as
this drug is not a substrate for ABC transporters, there was no in-
crease in Cdr1p levels (Fig. 3).
3.4. Cytotoxic activity of styrylquinolines
An MTT assay on normal human fibroblasts was performed to
examine the toxicity of styrylquinolines to human cells. The results
showed (Table 4) that three compounds (WK14, WK15 andWK15B)
had the same cytotoxicity value (0.1 mM), with WK14 and WK15
having comparable MIC50 and cell viability values. However, the cy-
totoxicity level of WK14B was >0.1 mM.
4. Discussion
Styrylquinolines consist of two aromatic parts connected by an
unsaturated ethylene linker that results in a flat rigid structure
with relatively high lipophilicity. Such molecules are generally
Fig. 2. Influence of styrylquinolines (half of minimum inhibitory concentration) on
energy-dependent rhodamine 6G efflux, 30 minutes after efflux was induced by ad-
dition of glucose (**P < 0.005; n = 3).
Fig. 3. Microscopic imagining of Candida albicans cells. (A) After treatment with styrylquinolines (half of minimum inhibitory concentration), amphotericin B (0.25 μg/mL)
or fluphenazine (10 μg/mL). (B) After treatment with WK14 and WK15 (0.4 mM). Top panels, differential interference contrast; middle panels, Cdr1p-GFP; bottom panels,
propidium iodine staining (n = 3).
Fig. 4. Cdr1p-GFP protein levels in crude protein extracts from cells after treat-
ment with styrylquinolines (half of minimum inhibitory concentration) as evidenced
by anti-GFP Western blot (n = 4). DMSO-treated Candida albicans cells were used as
a control.
174 J. Szczepaniak et al. / International Journal of Antimicrobial Agents 50 (2017) 171–176
expected to penetrate cell membranes effectively; moreover,
they may interact with lipid structures such as ergosterol. The
polyenes, such as AmB, are a class of these drugs [33]. Other com-
pounds with large, flat aromatic structures may act similarly,
including doxorubicin, tetracycline and thioridazine [34]. Lipo-
philic drugs are known for their unspecific interactions, disrupting
membrane integrity [35].
As a result of screening for antifungal activity of a large group
of styrylquinolines, four compounds with interesting structure–
activity relationships were selected for inclusion in this study.
WK14 andWK15 have a hydroxyl group on both the phenyl and
quinolone rings, and have a high antifungal activity, regardless of
the position of the –OH group. The use of both compounds at MIC50
causes membrane permeabilization in C. albicans (Fig. 3b). Replace-
ment of the –OH group with the –OAc group strongly reduces the
activity of these compounds (Table 2), which is consistent with other
reports [16]. The antifungal and anticandida properties of pheno-
lic compounds have been widely described, and they are known for
activity such as inactivation of enzyme production [36], antibiofilm
effects and anti-adhesive effects [37,38]. Some phenolic com-
pounds can damage the cell membrane of C. albicans [39,40], cause
considerable reduction in ergosterol biosynthesis [41], or bind to
chitin in the cell wall [42]. It appears that the –OH group plays an
important role in the destruction of fungal cells.
For further explanation of the effects of styrylquinolines on
ABC transporters in C. albicans cells, strains with deletions in
genes encoding Cdr1p and Cdr2p pumps were tested. The cells
with CDR1 deletion showed a significant increase in sensitivity to
styrylquinolines, suggesting that these compounds are Cdr1p sub-
strates. This indicates a possible mode of action as competitive
inhibitors of this transporter. In the case of WK14, a significant re-
duction in resistance was only observed in the case of double cdrΔ
mutant. Both observations imply that Cdr2p removes the tested
styrylquinolines from cells less effectively than Cdr1p.
Another strategy in combating fungal infections is to study the
synergism of a new class of compounds and existing antifungal
agents in order to maximize the antifungal effect. Promising syn-
ergismwas found betweenWK14B, WK15B and fluconazole against
strains of C. albicans. All styrylquinolines were tested in double-
diluted concentrations starting with MIC50. In this system, WK14
and WK15 with fluconazole were less active than WK14B and
WK15B (Table 3). Fluconazole is a substrate for the ABC and MFS
transporters of C. albicans. No synergistic effect was observed in
the case of the cdr1Δ strain. This presumably occurs because
styrylquinolines have only aminor effect on Cdr2p, as theMIC profile
of the cdr2Δ strain is comparable with that of the wild-type strain
(Table 2). Interestingly, the compound that had the highest syner-
gistic activity, WK14B, has acetoxy groups in both the phenyl and
quinolone rings, indicating that while the –OH group is important
for compound antifungal activity, the –OAc group increases syner-
gistic action.
Very similar results to wild-type strain MICs were obtained in
cytotoxicity testing using normal human fibroblast cells. This sug-
gests excluding the use of higher concentrations of styrylquinolines
as antifungal drugs. However, in combination, styrylquinolines in-
creased sensitivity to fluconazole in concentrations as little as 64
times lower than MIC50.
One of the hypotheses explaining the preference for some struc-
tures of compounds in synergistic activity is the competitive pumping
of compounds with varying intensity outside the cells. The exper-
iment with R6G showed that WK14 andWK14B significantly block
the efflux of R6G, unlike WK15 and WK15B (Fig. 2). It seems that
the substitution of the –OH or –OAc groups in the ortho position
on the quinolone ring reduced the affinity of these compounds for
the rhodamine-binding site in ABC transporters [43]. However, in
combination with fluconazole, WK15B was more active thanWK15,
indicating an additional but yet unknown mechanism of action.
The delocalization of Cdr1p from the membrane into the cell is
observed under certain conditions and in the presence of some com-
pounds [25,44]. Kumar et al [45] found that highermembrane fluidity
can lead to incorrect localization of the Cdr1p pump and a lack of
pump activity. In some cases, decreases in cellular ergosterol level
and mis-sorting of Cdr1p into vacuoles were observed during the
dysfunction of mitochondria [46]. The structures of styrylquinolines
and their lipophilic properties predispose them to accumulate in
cellular membranes. Their intrinsic mechanism of actionmay consist
of non-specific interactions or alteration of the arrangement of
ergosterol. Except for WK14B, the tested compounds caused intra-
cellular delocalization of Cdr1p (Fig. 4). One of the mechanisms of
action could be reducing the activity of Cdr1p and its relocation by
disrupting the construction of the membrane. Another study has
shown that some phenolic compounds significantly decrease the
expression levels of CDR1 and MDR1 genes in fluconazole-resistant
C. albicans [47]. However, the present results indicate an increase
in Cdr1p concentration in candida cells under the action of
styrylquinolines (Fig. 4), which suggests that the excess quantity of
transporter cannot anchor in the plasma membrane where Cdr1p
localization is supposed to occur.
5. Conclusions
Four promising styrylquinolines with high activity against patho-
genic fungi were tested for their anti-C. albicans activity. In
combination with fluconazole, the tested compounds showed syn-
ergistic interactions that may result from mutual efflux by Cdr
proteins. The styrylquinolines may also interact with the cell mem-
brane, leading to delocalization of pumps. These findings are
promising for designing novel antifungal agents. Highly active com-
pounds that disrupt natural fungal defence against xenobiotic
substances may be particularly desirable for effective therapy, which
is even more important in highly resistant strains of candida.
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